ZO Future Group (HKG:2309)
Hong Kong · Delayed Price · Currency is HKD 1.780
-0.050 (-2.73%)
Aug 13, 2025, 3:52 PM HKT
Achilles Therapeutics Income Statement
Financials in millions HKD. Fiscal year is July - June.
Millions HKD. Fiscal year is Jul - Jun.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2016 - 2020 |
|---|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 | Jun '20 Jun 30, 2020 | 2016 - 2020 |
Revenue | 303.56 | 275.24 | 217.1 | 220.94 | 165.02 | 231.53 | Upgrade |
Revenue Growth (YoY) | 20.23% | 26.78% | -1.74% | 33.88% | -28.73% | 10.02% | Upgrade |
Cost of Revenue | 663.96 | 570.56 | 418.21 | 465.55 | 427.14 | 449.87 | Upgrade |
Gross Profit | -360.4 | -295.31 | -201.11 | -244.61 | -262.11 | -218.34 | Upgrade |
Selling, General & Admin | 75.54 | 52.96 | 38.97 | 35.38 | 50.13 | 54.37 | Upgrade |
Operating Expenses | 132.04 | 96.28 | 71.81 | 100.7 | 126.99 | 138.7 | Upgrade |
Operating Income | -492.44 | -391.59 | -272.92 | -345.31 | -389.1 | -357.04 | Upgrade |
Interest Expense | -62.09 | -36.81 | -22.02 | -25.36 | -30.68 | -33.19 | Upgrade |
Interest & Investment Income | 8.45 | 8.35 | 2.86 | 8.97 | 17.9 | 7.8 | Upgrade |
Earnings From Equity Investments | -11.81 | -5.53 | - | - | - | - | Upgrade |
Currency Exchange Gain (Loss) | -1.45 | -7.06 | -3.22 | -16.98 | - | - | Upgrade |
Other Non Operating Income (Expenses) | 12.1 | 11.72 | 187.38 | 213.36 | -4.57 | 13.45 | Upgrade |
EBT Excluding Unusual Items | -547.24 | -420.93 | -107.92 | -165.33 | -406.45 | -368.98 | Upgrade |
Impairment of Goodwill | - | - | - | - | -5.6 | -2.21 | Upgrade |
Gain (Loss) on Sale of Investments | 27.18 | 7.82 | - | - | - | - | Upgrade |
Gain (Loss) on Sale of Assets | 111.31 | 152.62 | 40.44 | 33.2 | 351.08 | 115.54 | Upgrade |
Asset Writedown | -65.28 | -65.28 | -17.64 | -5.07 | -59.54 | -22.78 | Upgrade |
Other Unusual Items | 0.44 | - | 0.27 | 0.71 | 8.09 | 6.74 | Upgrade |
Pretax Income | -470.86 | -319.86 | -84.85 | -107.77 | -112.42 | -271.68 | Upgrade |
Income Tax Expense | -0.75 | -0.67 | 0.71 | -0 | -0.59 | -5.2 | Upgrade |
Earnings From Continuing Operations | -470.11 | -319.19 | -85.56 | -107.77 | -111.83 | -266.48 | Upgrade |
Minority Interest in Earnings | 207.15 | 136.41 | 59.9 | 67.11 | 37.6 | 6 | Upgrade |
Net Income | -262.96 | -182.78 | -25.66 | -40.66 | -74.23 | -260.48 | Upgrade |
Net Income to Common | -262.96 | -182.78 | -25.66 | -40.66 | -74.23 | -260.48 | Upgrade |
Shares Outstanding (Basic) | 804 | 782 | 772 | 772 | 738 | 708 | Upgrade |
Shares Outstanding (Diluted) | 804 | 782 | 772 | 772 | 738 | 708 | Upgrade |
Shares Change (YoY) | 4.19% | 1.35% | - | 4.55% | 4.17% | 30.32% | Upgrade |
EPS (Basic) | -0.33 | -0.23 | -0.03 | -0.05 | -0.10 | -0.37 | Upgrade |
EPS (Diluted) | -0.33 | -0.23 | -0.03 | -0.05 | -0.10 | -0.37 | Upgrade |
Free Cash Flow | -542.72 | -515.96 | -264.55 | -235.59 | -330.71 | -254.36 | Upgrade |
Free Cash Flow Per Share | -0.68 | -0.66 | -0.34 | -0.30 | -0.45 | -0.36 | Upgrade |
Gross Margin | -118.72% | -107.29% | -92.64% | -110.72% | -158.83% | -94.31% | Upgrade |
Operating Margin | -162.22% | -142.27% | -125.71% | -156.29% | -235.79% | -154.21% | Upgrade |
Profit Margin | -86.63% | -66.41% | -11.82% | -18.40% | -44.98% | -112.51% | Upgrade |
Free Cash Flow Margin | -178.78% | -187.46% | -121.86% | -106.63% | -200.41% | -109.86% | Upgrade |
EBITDA | -378.11 | -317.71 | -234.34 | -272.97 | -302.71 | -258.43 | Upgrade |
EBITDA Margin | -124.56% | -115.43% | -107.94% | -123.55% | -183.43% | -111.62% | Upgrade |
D&A For EBITDA | 114.33 | 73.88 | 38.58 | 72.35 | 86.39 | 98.61 | Upgrade |
EBIT | -492.44 | -391.59 | -272.92 | -345.31 | -389.1 | -357.04 | Upgrade |
EBIT Margin | -162.22% | -142.27% | -125.71% | -156.29% | -235.79% | -154.21% | Upgrade |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.